Karyopharm to Report First Quarter 2017 Financial Results on May 4, 2017
April 27 2017 - 07:00AM
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage
pharmaceutical company, announced today that it will report first
quarter 2017 financial results and provide a company update on
Thursday, May 4, 2017. Karyopharm's management team will host a
conference call and audio webcast at 8:30 a.m. ET on Thursday, May
4, 2017 to discuss the financial results and recent business
developments.
To access the conference call, please
dial (855) 437-4406 (local) or (484) 756-4292
(international) at least five minutes prior to the start time and
refer to conference ID 10603764. A live audio webcast of the call
will be available under "Events & Presentations" in the
Investor section of the Company's
website, investors.karyopharm.com/events.cfm. An archived
webcast will be available on the Company's website approximately
two hours after the event.
About Karyopharm
Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a
clinical-stage pharmaceutical company focused on the discovery and
development of novel first-in-class drugs directed against nuclear
transport and related targets for the treatment of cancer and other
major diseases. Karyopharm's SINE™ compounds function by binding
with and inhibiting the nuclear export protein XPO1 (or CRM1). The
Company's initial focus is on seeking regulatory approval and
commercialization of its lead drug candidate, oral selinexor
(KPT-330). To date, over 1,900 patients have been treated with
selinexor and it is currently being evaluated in several mid- and
later-phase clinical trials across multiple cancer indications,
including multiple myeloma in combination with low-dose
dexamethasone (STORM) and backbone therapies (STOMP), diffuse large
B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others.
Karyopharm plans to initiate a pivotal randomized Phase 3 study of
selinexor in combination with bortezomib (Velcade®) and low-dose
dexamethasone (BOSTON) in patients with multiple myeloma in early
2017. In addition to single-agent and combination activity against
a variety of human cancers, SINE™ compounds have also shown
biological activity in models of neurodegeneration, inflammation,
autoimmune disease, certain viruses and wound-healing. Karyopharm,
which was founded by Dr. Sharon Shacham, currently has five
investigational programs in clinical or preclinical development.
For more information, please visit www.karyopharm.com.
Contacts:
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Mar 2023 to Mar 2024